Safety of voriconazole and dose individualization

被引：58

作者：

Lutsar, I ^{[1
]}

Hodges, MR ^{[1
]}

Tomaszewski, K ^{[1
]}

Troke, PF ^{[1
]}

Wood, ND ^{[1
]}

机构：

[1] Pfizer Ltd, Global Res & Dev, Sandwich CT13 9NJ, Kent, England

来源：

关键词：

D O I：

10.1086/374248

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：1087 / 1088

页数：2

共 6 条

[1] A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients
Ally, R
Schürmann, D
Kreisel, W
Carosi, G
Aguirrebengoa, K
Dupont, B
Hodges, M
Troke, P
Romero, AJ
[J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) : 1447 - 1454
[2] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
Herbrecht, R
Denning, DW
Patterson, TF
Bennett, JE
Greene, RE
Oestmann, JW
Kern, WV
Marr, KA
Ribaud, P
Lortholary, O
Sylvester, R
Rubin, RH
Wingard, JR
Stark, P
Durand, C
Caillot, D
Thiel, E
Chandrasekar, PH
Hodges, MR
Schlamm, HT
Troke, PF
de Pauw, B
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) : 408 - 415
[3] The safety of voriconazole
Potoski, BA
Brown, J
[J]. CLINICAL INFECTIOUS DISEASES, 2002, 35 (10) : 1273 - 1275
[4] TAN KKC, 2001, 41 INT C ANT AG CHEM
[5] *US FDA, 2001, BRIEF DOC VOR OR INT
[6] Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
Walsh, TJ
Pappas, P
Winston, DJ
Lazarus, HM
Petersen, F
Raffalli, J
Yanovich, S
Stiff, P
Greenberg, R
Donowitz, G
Lee, J
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 225 - 234